Hims & Hers Health, Inc. (HIMS)
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?
HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.
Hims & Hers Health: Under-Appreciated Upside
Hims & Hers Health is aggressively expanding through new product launches, international markets, and strategic acquisitions, supporting a bullish outlook. HIMS targets $6.5 billion in 2030 revenue, leveraging a subscriber base with significant runway to reach a 10 million target. Management signals potential to exceed long-term targets, reinforced by a $250 million share buyback reflecting confidence in undervalued shares.
Hims & Hers: Capitalizing On Robust Subscriber/ARPU Growth - Upgraded Buy Rating
HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international expansion through M&A activities, and strong operating leverage underpin HIMS' long-term revenue and EBITDA growth prospects. Regulatory headwinds from the FDA and new legislation pose near-term risks, but management remains confident in GLP-1 monetization and compliance.
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts
Hims & Hers Health, Inc. (HIMS) reached $35.45 at the closing of the latest trading day, reflecting a +2.12% change compared to its last close.
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
Hims & Hers: A Great Moment To Buy The Dip
Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into new specialties and diagnostics, with international growth representing a $1 billion medium-term opportunity. Q3 revenue grew 49% y/y to $599 million, beating expectations, with subscriber growth and rising average revenue per subscriber driving strong fundamentals.
HIMS Stock On A Losing Spree: Here's Why
Hims & Hers Health (HIMS) stock has experienced a 7-day losing streak, resulting in total losses of 8.7% over this time frame. The company's market capitalization has plummeted by approximately $699 million in the past week, currently sitting at $7.3 billion.
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?
Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.
Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows
HIMS deepens its subscription-led model with new care verticals, diagnostics and global expansion to boost retention.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
